American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 338-340, February 2007

Vitreal Penetration of Oral and Topical Moxifloxacin in Humans

  • Jeffrey J. Fuller, MD

      Affiliations

    • Department of Ophthalmology & Visual Science, University of Iowa, Iowa City, Iowa
    • ,
  • McGregor N. Lott, MD

      Affiliations

    • Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia
    • Corresponding Author InformationInquiries to McGregor N. Lott, MD, Department of Ophthalmology, Medical College of Georgia, 1120 15th Street, BA-2701, Augusta, GA 30912
    • ,
  • Nathanael M. Henson, MD

      Affiliations

    • Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia
    • ,
  • Asmaa A. Bhatti, MD

      Affiliations

    • Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia
    • ,
  • Harinderjit Singh, MD, FRCS(C)

      Affiliations

    • Southeast Retina Center, Augusta, Georgia
    • ,
  • Gerald McGwin Jr, MS, PhD

      Affiliations

    • Department of Epidemiology and Ophthalmology, University of Alabama at Birmingham, Callahan Eye Foundation Hospital, Birmingham, Alabama
    • ,
  • Dennis M. Marcus, MD

      Affiliations

    • Southeast Retina Center, Augusta, Georgia

Accepted 6 September 2006. published online 23 October 2006.

Purpose

To investigate the vitreal penetration of moxifloxacin after oral and topical administration.

Design

Prospective, nonrandomized clinical trial.

Methods

Twenty-four patients were assigned to one of four dosing groups: control (n = 3), which received no medication; oral (n = 8), which received two 400 mg oral doses of moxifloxacin before surgery; topical (n = 8), which received one drop of topical moxifloxacin 0.5% every 15 minutes for the hour preceding surgery; and combined (n = 5), which received two 400 mg oral doses and one drop of topical moxifloxacin 0.5% hourly for 18 hours prior to surgery. Vitreous samples were obtained and analyzed.

Results

Control, below quantifiable levels; oral, 1.553 ± 0.33 μg/ml; topical, 0.027 μg/ml; and combined, 2.219 ± 0.71 μg/ml. One topical patient developed postoperative endophthalmitis.

Conclusions

In contrast to topical moxifloxacin, oral moxifloxacin achieves significant levels in the noninflamed human vitreous.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors indicate no financial support or financial conflict of interest in this study. Involved in design of study (J.J.F, D.M.M.); Involved in collection, management, analysis and interpretation of data, and preparation of the data (J.J.F., M.N.L., H.S., G.M. Jr., D.M.M.); Involved in collection of data (J.J.F., M.N.L., N.M.H., A.A.B., H.S., G.M. Jr., D.M.M.); and involved in management, statistical analysis and interpretation of the data, and preparation of the manuscript (J.J.F., M.N.L., N.M.H., A.A.B., G.M. Jr., D.M.M.).Medications for this study were provided by Bayer Corporation and Alcon Laboratories, Inc. Analysis of vitreous specimens by high-performance liquid chromatography was performed by Alcon Laboratories, Inc.

PII: S0002-9394(06)01076-2

doi:10.1016/j.ajo.2006.09.023

American Journal of Ophthalmology
Volume 143, Issue 2 , Pages 338-340, February 2007

Article Tools